About pertuzumab
HER2-targeted monoclonal antibody
Used for
- Treats HER2-positive breast cancer with other cancer medicines.
- Used before or after surgery, or for advanced breast cancer.
Usual adult dose
840 mg by intravenous infusion initially, then 420 mg every three weeks; used with other medicines.
Common side effects
- Diarrhea
- Nausea
- Hair loss
- Low white blood cell counts
Important warnings
- Can cause serious infusion reactions or allergic reactions.
- May cause heart problems; heart function is monitored during treatment.
- Can harm an unborn baby; pregnancy testing and effective contraception are required.
- Use only for cancers confirmed to be HER2-positive.
Pregnancy
Can cause fetal harm. Avoid during treatment and for 7 months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for 7 months after the last dose.
Interactions
- No major drug interactions are established; tell the treatment team about all medicines and supplements.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.